Subscribe
shutterstock_1425438833_ii-studio
II.studio / Shutterstock.com
25 November 2019Big PharmaSarah Morgan

Novartis in $9.7bn deal to buy cholesterol drugmaker

Swiss drug company Novartis has agreed to buy The Medicines Co for $9.7 billion, as it focuses on expanding its cardiovascular portfolio.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Novartis to boost eye care portfolio with $3.4bn buy
10 May 2019   Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Big Pharma
Novartis to boost eye care portfolio with $3.4bn buy
10 May 2019   Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.

More on this story

Big Pharma
Novartis to boost eye care portfolio with $3.4bn buy
10 May 2019   Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims